Home
About
RWE
CME Activities
Blog
Library
Get Started
Real‑World Data Confirms T‑DXd’s Efficacy and Manageable Safety Across all HER2 Expression Levels.
Click Here for Summary/Action
T‑DM1 retains meaningful benefit in heavily pretreated, more complex real‑world populations, supporting its role as a standard HER2‑targeted option.
Click Here for Summary/Action
Tucatinib provides durable HER2+ mBC treatment persistence and meaningful rwTTD post‑T‑DXd for many with brain mets, multiple prior lines.
Click Here for Summary/Action
Signals suggest earlier use of T-DXd may improve patient outcomes.
Click Here for Summary/Action
This initiative has been supported by unrestricted educational grants from
Daiichi Sankyo, Inc. and AstraZeneca
